Quarterly report pursuant to Section 13 or 15(d)

Accounting Policies and Merger Pro Forma Adjustments - Schedule of Pro Formo Weighted Average Common Shares Outstanding (Details) (Parenthetical)

v3.21.1
Accounting Policies and Merger Pro Forma Adjustments - Schedule of Pro Formo Weighted Average Common Shares Outstanding (Details) (Parenthetical) - All Shares Issued/Issuable Upon Merger [Member]
 3 Months Ended
Mar. 31, 2021
shares
Akers pre-merger [Member]  
Common shares issued and outstanding 8,326,730 [1]
Akers pre-merger [Member] | Akers Biosciences, Inc. and Subsidiaries [Member]  
Common shares issued and outstanding 8,326,730
MyMD Pharmaceuticals, Inc., [Member] | MYMD pre-merger [Member]  
Conversion of stock, description Exchange Ratio of 0.7718
Reverse stock split 1-for-2 reverse stock split
Reverse split basis at the exchange ratio 0.7718
Common shares issued and outstanding 73,911,413
[1] The Company's pre-Merger common shares issued and outstanding of 8,326,730 was the actual number of common shares issued and outstanding as of March 31, 2021.